GSE107865

PBMC gene expression from Crohn's disease patients before Infliximab therapy.

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

About 40% IBD patients treated with anti-TNF antibodies do not respond to therapy. Baseline biomarkers of response are therefore of interest. By combining computational deconvolution of gene expression and meta-analysis approaches we identified cellular biomarkers in tissue (validated in 2 cohorts by IHC of biopsies), and investigated associated gene biomarkers in blood. This dataset provides data from the validation cohort III (blood).

Overall design

Whole blood samples were collected from 22 patients diagnosed with Crohn's disease, just before starting anti-TNF therapy (Infliximab). All patients were naive to anti-TNF. Response to therapy was assessed after 14 weeks based on changes in CRP and Calprotectin, as well as endoscopy (Responders: 17; Non-responders: 5). The prognostic power of genes identified to be related to cellular biomarkers identified from meta-analysis of public datasets of biopsy tissues were investigated.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
22 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

2 linked publications 2 DOIs

Primary publication

  1. Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD. Gut, 2019

Related publications

  1. Integrated Gene Expression Profiling Analysis Reveals Probable Molecular Mechanism and Candidate Biomarker in Anti-TNFα Non-Response IBD Patients. Journal of inflammation research, 2020
Available

Metadata Quality Components

Analysis Readiness

Not ready
55% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • Critical dataset warnings must be resolved.

Next Steps

  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

Critical dataset warnings are present.

Assay context may require expert handling before DESeq2-style analysis.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease, inflammatory bowel disease Disease context came from Normalization rules.
  • Likely case group Crohn's disease 22 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Interpreted disease metadata: Crohn's disease, Inflammatory bowel disease.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 2 publications; 2 DOIs available: PMID 29618496, PMID 32104045.
  • Publication context: Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD.. Gut, 2019. PMID 29618496. DOI 10.1136/gutjnl-2017-315494.
  • Publication context: Integrated Gene Expression Profiling Analysis Reveals Probable Molecular Mechanism and Candidate Biomarker in Anti-TNFα Non-Response IBD Patients.. Journal of inflammation research, 2020. PMID 32104045. DOI 10.2147/JIR.S236262.

Cautions

  • Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%.
  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Biofluid. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

115 fields

Sample Group Preview

22 rows shown
Show Hide
Study totals: Case 22 | Control 0 | Unassigned 0 | Excluded 0 | Ambiguous 0 22 rows shown
Group Role Accession Title Source / characteristics Reason
Crohn's disease Case GSM2882184 HR-42-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-42;Time:V1;Status:Responder;CRP:3.44;HBI:0;BMI:23.038752362949;Status_time:W14; Treatment: None; Patient: HR-42; Time: V1; Status: Responder; Crp: 3.44; Hbi: 0; Bmi: 23.038752362949; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882185 HR-44-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-44;Time:V1;Status:Responder;CRP:19.6;HBI:2;BMI:26.6727632982777;Status_time:W14; Treatment: None; Patient: HR-44; Time: V1; Status: Responder; Crp: 19.6; Hbi: 2; Bmi: 26.6727632982777; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882186 HR-46-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-46;Time:V1;Status:Responder;CRP:6.82;HBI:2;BMI:26.643598615917;Status_time:W14; Treatment: None; Patient: HR-46; Time: V1; Status: Responder; Crp: 6.82; Hbi: 2; Bmi: 26.643598615917; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882187 HR-47-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-47;Time:V1;Status:Responder;CRP:125.7;HBI:6;BMI:21.875;Status_time:W14; Treatment: None; Patient: HR-47; Time: V1; Status: Responder; Crp: 125.7; Hbi: 6; Bmi: 21.875; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882188 HR-48-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-48;Time:V1;Status:Responder;CRP:1.8;HBI:0;BMI:23.0400201994698;Status_time:W14; Treatment: None; Patient: HR-48; Time: V1; Status: Responder; Crp: 1.8; Hbi: 0; Bmi: 23.0400201994698; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882189 HR-29-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-29;Time:V1;Status:Responder;CRP:4.9;HBI:0;BMI:21.4995968825585;Status_time:W14; Treatment: None; Patient: HR-29; Time: V1; Status: Responder; Crp: 4.9; Hbi: 0; Bmi: 21.4995968825585; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882190 HR-30-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-30;Time:V1;Status:Non-responder;CRP:15.8;HBI:22;BMI:29.7339004102526;Status_time:W14; Treatment: None; Patient: HR-30; Time: V1; Status: Non-responder; Crp: 15.8; Hbi: 22; Bmi: 29.7339004102526; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882191 HR-31-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-31;Time:V1;Status:Responder;CRP:44;HBI:7;BMI:22.0385674931129;Status_time:W14; Treatment: None; Patient: HR-31; Time: V1; Status: Responder; Crp: 44; Hbi: 7; Bmi: 22.0385674931129; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882192 HR-32-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-32;Time:V1;Status:Non-responder;CRP:16.5;HBI:NA;BMI:NA;Status_time:W14; Treatment: None; Patient: HR-32; Time: V1; Status: Non-responder; Crp: 16.5; Hbi: NA; Bmi: NA; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882193 HR-33-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-33;Time:V1;Status:Responder;CRP:21.17;HBI:4;BMI:18.796189499765;Status_time:W14; Treatment: None; Patient: HR-33; Time: V1; Status: Responder; Crp: 21.17; Hbi: 4; Bmi: 18.796189499765; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882194 HR-35-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-35;Time:V1;Status:Responder;CRP:27;HBI:1;BMI:19.974407790019;Status_time:W14; Treatment: None; Patient: HR-35; Time: V1; Status: Responder; Crp: 27; Hbi: 1; Bmi: 19.974407790019; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882195 HR-36-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-36;Time:V1;Status:Non-responder;CRP:82.7;HBI:1;BMI:19.4674012855831;Status_time:W14; Treatment: None; Patient: HR-36; Time: V1; Status: Non-responder; Crp: 82.7; Hbi: 1; Bmi: 19.4674012855831; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882196 HR-37-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-37;Time:V1;Status:Responder;CRP:4.26;HBI:13;BMI:23.5102040816327;Status_time:W14; Treatment: None; Patient: HR-37; Time: V1; Status: Responder; Crp: 4.26; Hbi: 13; Bmi: 23.5102040816327; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882197 HR-20-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-20;Time:V1;Status:Responder;CRP:15.6;HBI:8;BMI:21.295294753921;Status_time:W14; Treatment: None; Patient: HR-20; Time: V1; Status: Responder; Crp: 15.6; Hbi: 8; Bmi: 21.295294753921; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882198 HR-39-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-39;Time:V1;Status:Responder;CRP:2.62;HBI:0;BMI:26.6727632982777;Status_time:W14; Treatment: None; Patient: HR-39; Time: V1; Status: Responder; Crp: 2.62; Hbi: 0; Bmi: 26.6727632982777; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882199 HR-22-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-22;Time:V1;Status:Responder;CRP:2.16;HBI:4;BMI:20.0183654729109;Status_time:W14; Treatment: None; Patient: HR-22; Time: V1; Status: Responder; Crp: 2.16; Hbi: 4; Bmi: 20.0183654729109; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882200 HR-23-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-23;Time:V1;Status:Non-responder;CRP:5.7;HBI:12;BMI:19.4463667820069;Status_time:W14; Treatment: None; Patient: HR-23; Time: V1; Status: Non-responder; Crp: 5.7; Hbi: 12; Bmi: 19.4463667820069; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882201 HR-24-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-24;Time:V1;Status:Responder;CRP:2.44;HBI:1;BMI:24.5674740484429;Status_time:W14; Treatment: None; Patient: HR-24; Time: V1; Status: Responder; Crp: 2.44; Hbi: 1; Bmi: 24.5674740484429; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882202 HR-26-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-26;Time:V1;Status:Non-responder;CRP:3.1;HBI:1;BMI:13.2330451608876;Status_time:W14; Treatment: None; Patient: HR-26; Time: V1; Status: Non-responder; Crp: 3.1; Hbi: 1; Bmi: 13.2330451608876; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882203 HR-27-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-27;Time:V1;Status:Responder;CRP:19.2;HBI:7;BMI:17.2110868084191;Status_time:W14; Treatment: None; Patient: HR-27; Time: V1; Status: Responder; Crp: 19.2; Hbi: 7; Bmi: 17.2110868084191; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882204 HR-28-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-28;Time:V1;Status:Responder;CRP:1.6;HBI:2;BMI:NA;Status_time:W14; Treatment: None; Patient: HR-28; Time: V1; Status: Responder; Crp: 1.6; Hbi: 2; Bmi: NA; Status_time: W14 Case marker detected.
Crohn's disease Case GSM2882205 HR-40-V1 Peripheral blood mononuclear cells Disease state: Crohn's disease;Treatment:None;Patient:HR-40;Time:V1;Status:Responder;CRP:1;HBI:4;BMI:24.3823729785937;Status_time:W14; Treatment: None; Patient: HR-40; Time: V1; Status: Responder; Crp: 1; Hbi: 4; Bmi: 24.3823729785937; Status_time: W14 Case marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.